Williams-Sonoma reported 'record' diluted EPS of $8.84 while net income declined 3.3% and operating margins contracted 50 basis points. The 10-K reveals this paradox: a $49M multi-year freight correction inflated FY2024 margins by 70bp, making FY2025's 'decline' an accounting phantom. Normalize for the freight ghost and a calendar artifact, and operating margins actually improved 40bp — the opposite of consensus. Meanwhile, $854M in buybacks manufactured the EPS record from a shrinking denominator, and Q4 tariff costs accelerated 4.25x, setting up a H1 FY2026 margin valley the market may be mispricing.
Boeing reported $2.48 in earnings per share for FY 2025 — its first profitable year since 2019 on 600 commercial deliveries. But the 10-K reveals adjusted EPS of -$9.35 after stripping a $9.6 billion divestiture gain that even Boeing's own 'core' non-GAAP metric fails to remove. The 737 recovery is generating real value at 4.8% incremental margin, but $8.4 billion in 777X losses consumed every dollar. At $216, investors are pricing in a turnaround the filing confirms is underway — but slower and more expensive than any headline metric reveals.
Intercontinental Exchange delivered 20.7% EPS growth on 7% revenue growth in FY2025 — a 95% incremental margin that screams compounding monopoly. But the 10-K reveals operating cash flow grew just 1.1%, the '51% recurring revenue' claim masks a largest segment that's 62% transactional, and $160 billion in clearinghouse assets make every screener metric wrong. At 28× earnings, the filing quietly contradicts the growth narrative.
Amphenol's FY2025 10-K contains a number that doesn't belong in a connector company's filing: 31% operating margins in Communications Solutions. The segment nearly doubled revenue to $12.1 billion, generating software-like profitability on physical connectors. But the same filing reveals that APH's $10.5 billion CommScope CCS acquisition — the second piece of a $12.6 billion systematic dismantlement — will dilute those margins by 150-300 basis points in 2026. The investment question: is the franchise expanding faster than margins are diluting?
Biogen reported GAAP EPS of $8.79 — a 21% decline — while simultaneously beating Non-GAAP guidance at $15.28 per share. The $957 million gap between these two numbers is the widest percentage divergence among large-cap biotechs. The 10-K reveals that 'core' operating income actually improved 1%, that the U.S. franchise grew 12.9% while Biogen physically retreated from European markets, and that anti-CD20 royalty margins at 56% are structurally compressing profitability even as headline revenue stabilizes. At 14.1x adjusted operating earnings with zero shareholder returns, the stock is a bet on whether $5.3 billion in pipeline commitments can replace what the MS franchise is losing.
Amgen reported $7.7 billion in net income for FY2025 — an 88.5% surge. But operating cash flow fell 13.3%, free cash flow collapsed 22%, and accounts receivable spiked 41% against just 10% revenue growth. Meanwhile, buried in the product revenue footnote: growth products overtook legacy at-risk drugs for the first time. The patent cliff narrative is partially obsolete — but a $12.3 billion debt maturity wall and negative ROIIC complicate everything.
Airbnb grew revenue 10% to $12.2 billion in FY2025, yet EPS declined. The explanation is not the investment cycle Wall Street cites — it is a double squeeze the filing reveals but earnings coverage misses. Interest income of $705M (22.5% of pretax profit) is eroding as rates fall, while field operations and policy costs are surging 34%, creating a structural expense floor that cannot be cut like advertising. At 33x earnings, the stock needs 17% annual EPS growth — the filing delivered -1.8%.
Wabtec reported $6.83 in GAAP EPS for FY2025 — but $461M of acquisition charges obscure a business generating 56% incremental gross margins and 17.5% adjusted operating margins. Meanwhile, $735M of off-balance-sheet working capital tools make the cash conversion cycle look 14 days better than it actually is. We apply a three-layer 'Acquisition Opacity Framework' to reveal the real economics behind the largest locomotive maker's most aggressive M&A year.
Dell Technologies reported record $113.5 billion in revenue and 36% EPS growth for fiscal 2026. But buried in the segment footnote of the annual report, ISG gross margin collapsed 550 basis points in a single year — even as the segment's operating income grew 30%. The company's $26 billion services layer and disciplined SG&A efficiency are masking a fundamental shift in earnings quality that the earnings release doesn't show.
First Solar reported $5.2 billion in revenue and 40.6% gross margins in FY2025, but the 10-K reveals $1,600 million in Section 45X credits constitute 75.5% of gross profit — and exactly offset the US production cost premium. With OBBBA 'severely limiting' these credits, we decompose whether a three-layer competitive barrier (AD/CVD duties up to 3,404%, TOPCon patent suits, FEOC restrictions) can convert subsidy dependence into pricing power.
MongoDB's free cash flow exploded 315% to $500 million in FY2026, pushing FCF margin to 20.3%. Wall Street fixated on the 17% revenue growth guide and sent the stock down 22%. But the 10-K reveals something neither bulls nor bears are discussing: nearly 100% of that $505 million in operating cash flow is consumed by a $499 million equity compensation recycling system — buybacks plus a brand-new net share settlement policy that annualizes to ~$300M/year. The real question isn't whether MongoDB can grow — it's whether the S&M leverage engine (47% → 38% of revenue in 3 years) can outrun this treadmill.
Marvell Technology grew revenue 42% to $8.2 billion in FY2026 — the fastest among major semiconductor companies. Free cash flow grew 0.2%. A $735.5 million receivables factoring program buried in an MD&A footnote inflates reported operating cash flow by up to 42%, while non-GAAP adjustments exceeding GAAP operating income create a dual-reality earnings picture. Five findings from the 10-K that aren't in any earnings summary.
Target Corporation reported its 57th consecutive year of dividend increases and called its SG&A rate 'flat.' But the FY2025 10-K reveals a $593 million interchange fee settlement masked a 30 basis point deterioration in the underlying cost base, adjusted operating income declined 14.2% — nearly twice the GAAP decline — and management's own $5 billion capex guide pushes projected free cash flow $538 million below the annual dividend. For the first time, Target must borrow to sustain the streak that defines it as an income stock.
CrowdStrike's Rule of 40 registers an impressive 49.2% — until you adjust for $1.1 billion in stock-based compensation that the metric treats as free. The adjusted score collapses to 26.4%, exposing a 38.5-percentage-point gap between cash returns (31.2%) and accrual returns (-7.2%). Meanwhile, DOJ and SEC probes have expanded beyond the July 19 outage into revenue recognition and ARR reporting, and three accounting tailwinds totaling $130-140M will inflate FY2027 margins. This is the real CrowdStrike hiding behind the headline numbers.
Ameriprise Financial reported a 'record' 53.2% adjusted operating ROE and 10.1% EPS growth in FY2025. But strip away three layers of earnings distortion — insurance fair value gains, buyback-driven share shrinkage, and management's adjusted metrics — and the company's core pretax income actually declined 3.8%. At $490 per share, the 10-K reveals an earnings engine running on borrowed altitude.
DoorDash reported its first full-year GAAP operating profit of $723 million on $13.7 billion in revenue — a milestone investors waited years to see. But the 10-K reveals three hidden subsidies: stock-based compensation 45% larger than operating income, $348 million in capitalized software that never hits the income statement, and a near-zero 0.75% tax rate from one-time acquisition benefits. True free cash flow was flat year-over-year at $1.83 billion, and $9.15 billion in real obligations don't appear on any debt line. The Profitability Gap Cascade — from management's $2.8B Adjusted EBITDA to $776M in commitment-adjusted free cash flow — is a 3.6:1 ratio, the widest among peers.
Edison International reported $11.55 in earnings per share for FY2025 — a 249% surge that pushed its PE ratio to 5.2x. But $2,591 million of that earnings explosion was non-core wildfire settlement recoveries, and core EPS was just $6.55. Meanwhile, the Eaton Fire recovery framework absorbed 98.7% of initial claims at just $13 million pre-tax net cost to shareholders. The catch: customer bad debts tripled to $397 million — 4.1% of authorized revenue — threatening the ratepayer-funded mechanism that makes the framework work. At $60 per share, Edison isn't just a wildfire bet — it's a bet on whether the recovery framework survives its own funding source deteriorating.
Keurig Dr Pepper reported $3.6 billion in operating income for FY2025 — a 38% year-over-year surge. But $865 million of that growth came from lapping prior-year impairment charges, all three operating segments show gross margin compression, and operating cash flow actually declined 10.3%. The filing reveals a business where organic operating income grew approximately 3.4%, appliance volume collapsed 19.9%, and the coming JDE Peet's acquisition will push pro-forma FCF payout to 93.6%.
LPL Financial's FY 2025 10-K reveals a paradox: record $2.4 trillion in advisory assets and 37% revenue growth alongside an 18.5% decline in GAAP earnings, negative operating cash flow of -$411 million, and a leverage reality (4.74x) that management's preferred metrics (1.95x) obscure by 2.8 turns. We decompose the $740 million acquisition toll, expose a 30:1 asymmetric rate risk in the hidden profit engine, and identify the specific integration milestones that determine whether Commonwealth was worth $2.7 billion.
Mondelez International's FY 2025 10-K reveals a $729M gap between input cost inflation and pricing recovery — but that's the number everyone can find. What the filing buries across three separate disclosures is how the company funded $5.5B in shareholder returns on just $2.3B in free cash flow: a 37-fold commercial paper surge, $3.6B in bank-intermediated 'supplier' payables, and a Board that quietly doubled the company's debt authorization. Neither the 44.7% GAAP EPS decline nor management's 12.8% adjusted figure tells the truth.
Altria Group paid $4.16 per share in dividends on $4.12 per share in earnings — a 101% GAAP payout ratio that screams 'unsustainable.' But the 10-K tells a different story: free cash flow grew 5.4% to $9.1 billion, covering the dividend at 1.29x. Meanwhile, smokeable operating income grew for three consecutive years despite falling revenue, driven by a structural mechanism where settlement costs decline faster than volume. The paradox deepens with $2.1 billion in NJOY write-downs, on! losing the pouch race to ZYN, and Marlboro shedding 1.5 share points in a single quarter.
Moderna reported a -158% operating margin on $1.9 billion in FY2025 revenue. But the 10-K reveals something the earnings release doesn't: Moderna's mRNA manufacturing platform produces vaccines at a 78.2% core gross margin — 23 percentage points higher than reported. The gap? $472 million in transitional costs that have declined 87% since 2023. With $8.1 billion in total financial assets providing 4.3 years of runway, and two date-certain catalysts (Europe lockout expiry Dec 2026, FDA flu vaccine decision Aug 5, 2026) approaching, the central question shifts from survival to revenue inflection timing.
The iShares Silver Trust (SLV) reported $21.3 billion in net income for FY2025 — on paper, more profitable than 98% of the S&P 500. But 83.3% of that income is unrealized silver gains that never produced a dollar of cash. Meanwhile, each share's silver backing has eroded 9.3% since inception because the trust sells silver to pay BlackRock's 0.50% annual fee — a fee BlackRock can raise without shareholder approval. The filing reveals a structurally simple but economically powerful fee extraction mechanism operating behind one of America's most popular commodity investments.
AbbVie buried $15 billion in non-cash charges inside its fiscal 2025 10-K — more than triple its reported net income. The 96x GAAP P/E collapses to 21x on a cash basis, but $25.4 billion in contingent consideration obligations and a franchise concentration reboot (42.3% of revenue in two drugs, heading to 51.5%) reveal the truth sits between the extremes.
Ameren Corporation reported 21% EPS growth in FY2025 — its strongest year in a decade. But the 10-K reveals that $0.83 of every $5.35 in earnings per share came from a non-recurring 8.5% effective tax rate, and the $387M rate case that powered the revenue surge was only effective for seven months. Our analysis normalizes earnings to $4.52/share, reconstructs the transmission segment's true 67.3% operating margin, and maps the PISA cap and earnings sharing constraints that bound Ameren's $20.8B growth story.
Ares Management reported a 1% GAAP operating margin on $4.76 billion in revenue — $46.9 million in operating income that makes a grocery store look profitable. But the same 10-K reveals $2,583 million in fee-related earnings hiding behind the GAAP facade, a 55:1 gap driven by $2.6 billion in partnership-structure consolidation costs. At 16.6x FRE with 30% growth and 61% margins, the stock looks cheap — until you account for $1.675 billion in contingent earnout liabilities due by June 2028, $1.38 billion in new floating-rate debt, and a $740 million SBC regime that persists for three more years.
CME Group posted record revenue of $6.5 billion, record average daily volume of 28.1 million contracts, and record earnings of $11.16 EPS in FY2025. But the 10-K reveals that 62% of pretax income growth came from reinvesting $164 billion in customer collateral — not from the exchange fee business. With a 97.8% dividend payout ratio and the Fed signaling rate cuts, CME's most important profit engine is entirely outside management's control.
Coupang reported $34.5 billion in revenue and a 1.4% operating margin — a number that prices it like a low-quality retailer. But the 10-K segment footnote reveals Product Commerce alone generated $2,485 million in EBITDA at an 8.4% margin, while Developing Offerings destroyed value on every incremental dollar with -3.7% marginal gross margins. Meanwhile, stock-based compensation consumed 100% of operating income, a 64.2% tax rate ate most of what remained, and a $1.2 billion data breach voucher program looms over Q1 2026. This is a profitable business voluntarily subsidizing a billion-dollar bet — wrapped in a geographic tax trap.
Johnson & Johnson reported $26.8 billion in net income for FY 2025 — a 90.5% surge driven almost entirely by a $7.0 billion talc reserve reversal. Strip that entry and normalized earnings grew just 5.5%, while free cash flow was flat and total debt surged 63% in two years. At $208, the stock trades at 23.4x normalized earnings — not the 18.9x the headline suggests. The 10-K reveals three concurrent risk clocks: a patent cliff hitting hardest in the U.S. (-7.6% STELARA erosion), a leveraged capital return strategy funded by $9.2 billion in new debt at 3-4x old rates, and a 93% FCF payout ratio that only works with continued borrowing.
3M reported adjusted earnings of $8.06 per share for FY 2025 — a 10% improvement. On the same page, GAAP earnings were $6.00 — a 17% decline. The $2.06 gap is the widest in 3M's 123-year history, driven by $3.2 billion in litigation payments filed as a discrete cash outflow for the first time. The filing reveals two fundamentally different companies: a recovering industrial generating 19% ROIC with expanding margins, or a declining litigant whose GAAP free cash flow is consumed by settlement obligations extending to 2036.
NextEra Energy reported adjusted earnings growth of 8.2% for FY2025 — and GAAP earnings decline of 2.1%. The 10-K reveals the difference: a $1.25 billion federal tax benefit that surged 8.3× in a single year, converting $4.5 billion in pretax income into $6.8 billion in net income. Strip it out, and investors at $80/share are paying 46× earnings for a company that burned $12 billion more cash than it generated. This is the story of America's largest clean energy company and the tax credit machine that holds its valuation together.
Pfizer reported $1.36 in GAAP earnings per share for FY2025 — while paying a negative effective tax rate for the third consecutive year. Strip the tax distortion and EPS falls to $1.04. But the Biopharma segment quietly earned $29.3 billion at a 47.9% margin, up 3.1 percentage points. The 10-K reveals two depletion clocks running simultaneously: $4.68B/year in intangible amortization mechanically lifting GAAP EPS, and $18.5B in patent cliff exposure destroying revenue — with the curves crossing in 2027-2028.
Republic Services grew free cash flow 15.8% to $2.4 billion in FY2025 — four and a half times faster than revenue. But the 10-K reveals the Q4 earnings beat was entirely tax-manufactured (3.4% ETR vs 21.5% Q1-Q3), revenue is decelerating on a 3-year arc (7.1% to 3.5% to a guided 3.0%), and acquisitions now account for 37% of total growth and rising. At 30.7x earnings, investors face a $6.1B 2029 refinancing wall and unquantified PFAS risk against $2.3B in closure obligations.
Thermo Fisher Scientific generated $44.6 billion in revenue in FY2025 and grew EPS 7.3% to $17.74. But free cash flow declined 13.4% to $6.29 billion. At 32.6× trailing earnings, the market embeds roughly $50 billion of enterprise value in TMO's ability to keep acquiring its way to growth. The 10-K reveals three hidden subsidies — $283 million in interest rate swap benefits, $16 billion in sub-3% legacy bonds repricing higher, and a declining amortization tailwind — propping up the earnings narrative while $14 billion in near-term obligations come due.
Union Pacific reported 'record-breaking' FY 2025 earnings of $11.98 per share, up 8%. But the 10-K reveals that only 18% of that growth came from actual railroad operations. The remaining 82% — industrial park land sales, share buybacks, and a one-time tax benefit — all disappear in FY 2026, creating a $0.55/share headwind that organic operations must replace. With the Norfolk Southern merger facing unprecedented regulatory scrutiny and no STB precedent, investors are paying ~$69/share for merger optionality they cannot handicap.
Xcel Energy reported 8.57% ongoing EPS growth in FY 2025 — right at the top of management's 6-8% target. But GAAP EPS actually fell 0.58%. The 10-K reveals a $10.9 billion capital machine operating at 3.68x depreciation, generating negative incremental returns (-0.86% ROIIC) while diluting shareholders 8.57% annually. Production tax credits don't benefit shareholders despite the -13.8% effective tax rate, AFUDC inflates 8.2% of net income, and wildfire charges classified as 'non-recurring' have now appeared in three of the past five years.
Elevance Health grew revenue $22.1 billion to $199 billion in FY 2025 — and lost $663 million in operating income doing it. The filing reveals a three-layer earnings mask: a non-recurring 880bp tax rate collapse ($593M benefit), a $666M settlement tailwind absorbed by cost deterioration, and aggressive buybacks exceeding free cash flow. At 13.9x trailing earnings the stock looks cheap, but at 15.5x normalized earnings, investors are pricing in growth that the operating trajectory doesn't support. Meanwhile, a $3.9 billion shadow exposure to Mosaic Health — a PE-backed joint venture — dwarfs the $732M headline.
Alphabet reported $132.2 billion in net income for FY2025 — a record. But the 10-K reveals $149.1 billion in contractually locked purchase commitments, $24.1 billion in unrealized equity gains inflating headline growth, and a tax timing benefit that boosted cash flow by $13.5 billion. Adjusted earnings grew 15.6%, not 32%, and free cash flow was flat. The investment question: can Google Cloud's 956-basis-point margin expansion convert the largest corporate infrastructure buildout in history into returns?
MercadoLibre generated $10.8 billion in free cash flow in FY 2025 — or $1.5 billion, depending on which line of its own 10-K you read. That $9.3 billion gap reveals a fintech business consuming 86% of cash flow for customer deposits and loan originations. Meanwhile, $1.1 billion in credit card receivable gains — classified as 'non-recurring' both years — represent 56% of net income, pushing the effective P/E from 51x to 117x. And Argentina, generating 3.6 times Brazil's adjusted operating margin in a hyperinflationary economy, supplies the profitability that makes the story work.
Marsh generated $5 billion in free cash flow in FY2025 — 25% more than the prior year — yet earnings per share grew just 3.1%. The 10-K reveals that the company's $7.75B McGriff acquisition compressed R&I segment margins by 160 basis points, with acquired revenue arriving at 14.1% incremental margin — half the existing 28.4% base. But beneath the GAAP noise, Marsh's cash conversion ratio of 1.27x is the highest among its financial services peers, and the company returned 89% of net income to shareholders while running a $400M efficiency program that the filing itself warns may not deliver.
Otis Worldwide spent $145 million on its UpLift restructuring program in FY2025 and realized $84 million in savings — a net cost of $61 million. The 10-K reveals the real margin engine isn't the restructuring investors have been told to watch: it's the mechanical decline of New Equipment, where Q4 margins hit a record-low 3.64%. With GAAP EPS down 14% and adjusted EPS up 6%, the $0.55 per-share gap between the two earnings realities creates fundamentally different valuations — 24.8x or ~29x — for the same company.
PNC Financial Services reported record 21% EPS growth in FY2025 — and the stock trades at 10x forward earnings, pricing in zero growth. Four widely-cited red flags explain the market's skepticism: collapsing cash flow, inflated earnings, a stagnant core segment, and stretched valuation. The 10-K disproves all four. But two genuine risks survive the correction cascade: capital markets revenue cyclicality (47% of fee growth from a +24% surge) and a concentrated CRE office maturity wall (57.7% criticized, 38.7% maturing in 12 months).
Simon Property Group reported $14.17 in EPS for FY2025 — a 95% increase that masks a ~25% decline in normalized earnings after stripping the $2.9B Taubman consolidation gain. The filing reveals the acquired TRG portfolio operates at roughly 37% NOI margin versus 75% for the legacy portfolio, compressing segment margins by 137 basis points. Meanwhile, The Mills format delivered 8.7% rent growth at 99.2% occupancy, challenging the monolithic 'dead mall' narrative. With $5.91B in 2026 debt maturities refinancing at a 73 basis point premium, SPG's 4.7% rent growth must outrun three convergent headwinds.
Welltower generated $10.8 billion in revenue in FY2025 and lost $480 million at the operating line. The gap between EPS ($1.39) and FFO per share ($4.45) — a 220% spread — is the widest among major REITs, driven by $1.5 billion in immediately-vested stock compensation. Meanwhile, $8.9 billion in equity issuance created a 12.1 percentage-point dilution drag, and UK revenue tripled overnight to 22.3% of the senior housing segment. At 42× FFO, the market is betting demographics will overcome all of it.
Bristol-Myers Squibb just reported the largest earnings swing in its history — net income reversed from a $8.9 billion loss to a $7.1 billion profit. Wall Street sees a recovery story. But the 10-K reveals free cash flow declined 7.9% to $12.8 billion, and three compression vectors — IRA pricing, an unprecedented government trade deal, and EU generics already launching — are converging on BMY's revenue faster than the market's 2028 patent cliff timeline implies. At 11.7% FCF yield, BMY is either the most undervalued cash generator in large-cap pharma or a controlled decline the market has priced correctly.
Gilead Sciences reported a 1,673% net income surge in its FY 2025 10-K — from $480 million to $8.5 billion. But buried in the filing's geographic revenue tables is a $636 million pricing gap no analyst has calculated: Biktarvy U.S. revenue grew 5.6% while international grew 11.5%. That gap is the IRA's real cost, derived from Gilead's own data. Meanwhile, the adjusted operating business grew 20%, normalized EPS is $6.42 not $6.78, and three regulatory threats are converging on the company's HIV franchise.
IBM reported a 76% net income surge in FY2025 — its best earnings growth in over a decade. Two weeks later, the stock crashed 13%, erasing $31 billion, when Anthropic announced Claude Code could automate COBOL modernization. The 10-K reveals both reactions were wrong: two non-recurring events inflated earnings by $3.1 billion, true growth was 8-9%, and consulting — the supposed AI victim — is only 17.1% of IBM's profit. The real story is a quiet software takeover generating 61.7% of segment profit at 31.1% margins.
Imperial Oil reported a 32% earnings collapse in FY 2025 — its steepest since the pandemic. But the 10-K's reconciliation tables reveal $1.031 billion in one-time charges (Norman Wells end-of-life and restructuring) explain 68% of the decline. Strip those out, and you find a company producing at a 30-year high of 438,000 boe/d, returning 142% of net income to shareholders, and funding the highest total shareholder yield (10.8%) among major energy peers — all while borrowing from ExxonMobil at 2.7%.
Stryker just posted its fourth consecutive year of double-digit revenue growth, crossing $25 billion. Operating margins expanded 314 basis points. But the 10-K reveals that $807 million of that expansion is an impairment swing — not operational efficiency. The annual cost of being a serial acquirer totals $1,659 million, exceeding Stryker's entire R&D budget, and all of it is excluded from the adjusted earnings that underpin a 41x multiple. Meanwhile, 68% of pre-tax income flows through international operations generating just 24% of revenue, and the German tax authority has assessed $754 million.
Vertex Pharmaceuticals reported $12.0 billion in FY 2025 revenue with an 86.2% gross margin — numbers that suggest a well-oiled biotech machine. But newly disclosed segment data reveals that $1.05 billion of Vertex's $1.65 billion COGS is royalty payments, not manufacturing costs. Strip out the royalties and the real product margin is 95.0%. The problem: Royalty Pharma is now seeking to double the royalty rate on ALYFTREK, Vertex's next-gen CF product — putting $200 million or more in annual EBIT at stake in a company where 98.5% of product revenue comes from cystic fibrosis.
Kenvue reported 41% EPS growth in FY2025 — its best result since separating from Johnson & Johnson. But the metric management actually uses to evaluate the business declined 4.6%. The entire recovery traces to $860 million in non-recurring accounting items: impairment cessation, separation cost winddown, and stock compensation forfeitures. Meanwhile, the company's Skin Health & Beauty segment suffered a 30% two-year profit collapse, three product ingredient categories face simultaneous FDA and litigation scrutiny, and 96% of the company's cash sits overseas — while Kenvue pays out 107.6% of net income in dividends. This is the final independent 10-K of a $15.1 billion consumer health company that has already agreed to be absorbed by Kimberly-Clark for $48.1 billion.
Palantir paid $23 million in taxes on $1.66 billion in pretax income — a 1.37% effective rate. The FY2025 10-K reveals exactly why: a single line item in the tax footnote worth $720 million that rises and falls with the stock price. That mechanism boosted reported net income by 19.4%, putting the real P/E closer to 247x than the reported 199x. The filing also shows that only 37% of the $11.2 billion remaining deal value is contractually binding, and that international commercial revenue grew just 2.4% in a year the company grew 56%. The business transformation is real — but so is the amplification.
Humana grew revenue 10.1% to $129.7 billion in FY2025 — and saw operating cash flow collapse 69% to $921 million. Management calls it 'timing,' but the filing's own receivables numbers explain only 28% of the $2.05 billion decline. Meanwhile, Q4 quietly ran at an estimated 106.6% combined ratio, Star Ratings plunged from 94% to 20% of members in 4+ star plans, and a $3.5 billion revenue headwind looms for 2026. The only bright spot: CenterWell's 5.96% margin engine generates 44.6% of segment profits from 17.3% of revenue.
Sherwin-Williams used the word 'record' nine times in its Q4 2025 earnings release. The 10-K tells a different story: GAAP income before taxes declined 3.3% to $3,338 million, the 27% FCF surge was nearly half capex normalization, and the $1.17-per-share gap between adjusted and GAAP EPS reflects restructuring and impairment charges entirely absent in FY2024. At 31× earnings, management's own 2–4% growth guidance leaves a 12-percentage-point gap between what the price assumes and what the filing supports. Meanwhile, the most aggressive PSG price increase in recent history tests whether contractor loyalty can absorb a 7% hike in a 'softer-for-longer' demand environment.
Norfolk Southern reported 10.2% EPS growth and 200 basis points of operating ratio improvement in FY 2025. Revenue grew $57 million — less than half a percent. The 10-K reveals that 100% of the earnings improvement came from cost cuts, while the pending $85B Union Pacific merger has inflated compensation by $154M, suppressed capex by 20%, and triggered customer defection. At $289, investors are buying a binary merger bet with asymmetric downside.
S&P Global posted a 42.2% operating margin in FY2025 — the highest since the IHS Markit merger. Two weeks later, the stock dropped 18%. The 10-K reveals that two definitively non-recurring tailwinds — $133M in merger cost elimination and a $273M disposition gain — account for approximately 270 of the 290-basis-point margin expansion, while $1,064M in annual deal amortization suppresses a 50% adjusted margin by 8 percentage points. Ratings generates 45.6% of segment profit at a 63.8% margin, powered by a 28% billed issuance surge that may not sustain. The market repriced growth from 14% to 9-10% — directionally correct, but the underlying quality may be mispriced from both directions.
Vertiv Holdings reported 168.8% net income growth in FY 2025, but our earnings quality decomposition reveals that $203.5 million — nearly one-quarter — came from a non-repeating tax rate correction. The remaining 76% is durable operating leverage on $10.2 billion in revenue, backed by a $15 billion backlog with SaaS-like deferred revenue visibility. But the filing also reveals asymmetric risks: no disclosed cancellation penalties on that backlog, a widening GAAP-to-adjusted earnings gap, and percentage-of-completion estimation risk that grows with project scale.
Amphenol posted 52% revenue growth, 450bps of margin expansion, and closed its largest acquisition in history. The stock dropped. DuPont decomposition explains why: 86% of the balance sheet growth came from a single quarter, and incremental returns fell below the cost of debt.
86% of Amazon's ROIC decline is capital turnover compression — not margin deterioration. The 10-K reveals why: $59B in new servers, a depreciation reversal on AI hardware, and $440B in irrevocable commitments. At $200B capex, the margin of safety is compressing.
Howmet Aerospace earns 34% gross margins with sole-source pricing power in jet engine castings — yet GAAP ROIC is only 18.6%. The FY2025 10-K reveals why: $4.5 billion in legacy goodwill from the Alcoa-Arconic spinoff chain sits on the balance sheet generating zero revenue. Tangible ROIC is 35%. Cash ROIC hit 28% in Q4. The market prices HWM at 59x earnings anyway — and a $1.8B acquisition is about to add more goodwill.
Meta's Family of Apps earns a 51.5% operating margin. Its ROIC is declining at -6.3 points per quarter. Both facts are true simultaneously. The gap between them reveals everything about the largest AI infrastructure bet in advertising history — and the accounting policies designed to make it look cheaper than it is.
Regeneron Pharmaceuticals reported $4,505 million in net income for FY2025 — a 2.1% increase that suggests stability through the EYLEA biosimilar storm. But the 10-K reveals operating income fell 10.4%, a $581.5 million equity securities windfall inflated Q3 earnings, the OBBBA tax law nearly doubled the effective rate, and $3.7 billion in share buybacks reduced diluted shares by 6.9%. A four-component earnings bridge shows that none of REGN's headline growth came from selling more drugs at better margins.
Boston Scientific has 69% gross margins. Abbott has 56%. Yet Abbott's ROIC is 2.6x higher. This paradox reveals something fundamental about capital efficiency in medical devices—and why screening for 'high margin' stocks can lead you astray.
The conventional wisdom says Visa is the safer, higher-quality payment stock. Our ROIC analysis tells a different story: Mastercard's 78% ROIC dwarfs Visa's 36%, and the reason reveals something important about how to read these metrics.
CL has the highest ROIC (34.4%), yet PG—with the lowest ROIC (23.9%)—shows the strongest improvement trajectory (+21.6% over 8 quarters). Meanwhile, KO's superior cash generation masks a $12 billion tax liability. Here's how to read beyond the headline metrics.
All three companies raised dividends in 2025. All three beat Q3 earnings estimates. But one has a $950 million hidden liability that most investors don't see. Progressive's 26.8% payout looks sustainable until you examine what's buried in the filing footnotes.
Oracle's -$10B Q2 free cash flow triggered alarm bells. Decomposition reveals the collapse is 70% working capital timing, not structural deterioration. The real story: $248B in off-balance sheet lease commitments dwarfs their $100B balance sheet debt. This is the largest infrastructure bet in enterprise software history.
Adobe's ROIC didn't just beat peers—it doubled in 8 quarters. The story isn't 'Adobe has high ROIC.' It's WHY it improved from 50% to 105% while Salesforce stayed at 12%. DuPont decomposition reveals the answer.
Three fuel cell companies target AI data center power, but execution quality varies dramatically. Bloom Energy's +4.5% ROIC vs Plug Power's -104% isn't a small difference—it's a fundamental divide between a functioning business and a value destroyer. Our SEC filing analysis reveals warning signs even for the winner.
At $25B market cap and 41x revenue, Rocket Lab prices in Neutron success. Our 5-pass filing analysis reveals what the narrative misses: Launch Services growth inflated 32% by catch-up accounting, backlog concentration (69% top 5) exceeds revenue concentration, and gross margins compressed from 55% to 37%. Here's what to watch before the rocket flies.
PSX 21% ROIC vs VLO 4.5%? The numbers lie. VLO's Cash ROIC is 23.3%—actually the highest. One-time California impairments distort the picture. Here's the analytical framework that matters.
CrowdStrike's 10-Q tells a rare story: risk factors that are actively materializing. Two risks escalated, one is new, and zero have been resolved. The July 19 incident created $101M+ in expenses, litigation with no disclosed maximum exposure, and management admissions that read like warnings, not disclaimers. This is a test case for reading risk factors seriously.
Centrus Energy (LEU) returned 264% in 2025 on the HALEU monopoly thesis. But SEC filings reveal a 69% collapse in core SWU pricing and negative gross profit. Meanwhile, Cameco (CCJ) delivered +88% gross profit growth with 530bps margin expansion.
VST's +321% appreciation prices in nuclear optionality, but ignores a $510M battery fire disaster and antitrust lawsuit. CEG's 'capacity price boom' masks 970bps margin spread between regions. TLN's 0.9x interest coverage means debt service consumes nearly ALL operating income. We analyzed 9 filings to surface what the market overlooks.
Two enterprise AI giants, two very different earnings quality profiles. Palantir (6/10) wins on cash conversion, accounting practices, and litigation risk. Snowflake (4/10) struggles with negative cash conversion (-0.47x) and aggressive software capitalization ($228M). Our 5-pass SEC filing analysis reveals what standard screeners miss.
LYFT has higher gross margin (42.6%) AND better earnings quality (7/10) than UBER. So why is LYFT barely profitable? The answer: OpEx. LYFT spends 42.2% of revenue on operating expenses vs UBER's 30.6%. Our 5-pass filing intelligence reveals how scale economics beat unit economics in rideshare.
Five cloud security platforms, five different approaches to shareholder value. Elastic (7/10) stands out with neutral accounting and sustainable SBC. CrowdStrike (4/10) raises red flags with 22.9% SBC/revenue and multi-front July 19 litigation. Our 5-pass filing intelligence reveals what standard screeners miss.
Earnings can be manipulated through accounting choices. Cash flow cannot. Our earnings quality research library covers OCF/NI ratios, FCF consistency, stock-based compensation dilution, depreciation divergence, and buyback effectiveness—everything you need to separate real profits from accounting fiction.
Learn how to monitor $370B in AI infrastructure spending quarterly with a 3-metric framework. Track capex/revenue trends, depreciation manipulation signals, and growth alignment across Google, Microsoft, Amazon & Meta. Updated December 2025 with Meta's $600B commitment and Michael Burry's depreciation thesis.
Michael Burry warns Big Tech will understate depreciation by $176B through 2028. Amazon is taking a contrarian approach—shortening useful lives and accepting a $700M profit hit while peers extend to boost earnings. Learn how to screen for earnings quality using the capex/depreciation ratio.
Earnings quality measures how sustainable and real a company's profits are. High-quality earnings convert to cash; low-quality earnings are accounting tricks. This guide shows you exactly how to evaluate any company using our 3-metric framework with original data.
Three major fintechs, three very different approaches to earnings quality. PayPal (8/10) represents conservative accounting, Block (6/10) shows aggressive tendencies with regulatory exposure, and Coinbase (4/10) raises red flags with 0.10x cash conversion. Our 5-pass filing intelligence reveals what standard screeners miss.
Earnings can be manipulated through accounting choices. Cash flow cannot. Learn the cash conversion framework—synthesizing Damodaran's multi-period analysis, Greenwald's earnings power value, and Sloan's accruals anomaly—to separate real profits from accounting fiction.
AMD generates $1.72 in cash per $1 of profit—the best in semiconductors—while NVIDIA manages only $0.84. This signals AMD's earnings are higher quality and more sustainable despite NVIDIA's explosive growth.